Table II.
Incidence of hematologic toxicity observed during lenalidomide-alone therapy (n = 16).
| Toxicity | Grade 2 (n) | Grade 3 (n) |
|---|---|---|
| Anemia | 5 (31%) | 1 (6%) |
| Thrombocytopenia | 2 (12%) | 3 (19%) |
| Neutropenia | 5 (31%) | 1 (6%) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.